Screener / SEC EDGAR /CIK 0001588978 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

PROCEPT BioRobotics Corp PRCT

Compare with peers Embed
SEC comment letters, last 20 years

1 review of PRCT's filings by SEC staff

UPLOAD and CORRESP
Reviews 1 latest letter Jul 23, 2021
Questions asked 26 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 3 UPLOAD
  2. 2. Questions in them 26 numbered comments
  3. 3. Company replies 5 CORRESP
  4. 4. Reviews closed 0 of 1 closing letter

Form S-1

2021-07-23 to 2021-09-10 · 26 questions · 3 letters from the SEC, 5 from the company
No closing letter
Risk factorsRevenueResults discussion (MD&A)Critical estimatesLeases
Draft Registration Statement on Form S-1 submitted June 25, 2021 · Market and Industry Data, page ii
SEC asked (1)
We note your statement cautioning investors not to give undue reliance to estimates or market data included in the prospectus. Such statement may imply an inappropriate disclaimer of responsibility with respect to the third party information; therefore, please either remove the potential disclaiming language or clearly state in this section whether such information is reliable and that you are liable for such
Rest of the question

information. Our Company, page 1

PRCT answered
On behalf of PROCEPT BioRobotics Corporation (the “Company”), we submit this letter (this “Letter”) to the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”). The Company originally filed the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) with the Commission on August 18, 2021. The purpose of this Letter is to provide supplemental information to the Staff with respect to the accounting treatment for stock-based compensation.
Rest of the letter

In particular, the Company references Comment #12 of the Staff’s letter dated July 23, 2021 with respect to providing an explanation for the determination of the fair value of the common stock underlying the Company’s equity issuances and the reasons for any differences between the recent valuations of its common stock and the estimated offering price. The supplemental response set forth below is based upon information provided to Latham & Watkins LLP by the Company. On behalf of the Company, we are respectfully requesting confidential treatment for specified portions of this letter pursuant to Rule 83 promulgated by the Commission (17 C.F.R. § 200.83). This letter is accompanied by such request for confidential treatment because of the commercially sensitive nature of the information discussed in this letter. A redacted version of this letter will be filed with the Commission on EDGAR, omitting the confidential information. The Company’s discussion of its accounting for stock-based compensation is primarily contained within the sections of the Registration Statement titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates—Stock-Based Compensation” and “—Common Stock Valuations” (the “MD&A”) and appears on pages 98-100 of the Registration Statement. The Company supplementally advises the Staff that, while not reflected in the Registration Statement, based on discussions with the Company’s Board of Directors (the “Board of Directors”) and reflecting the input from the underwriters for its initial public offering (“IPO”), the Company currently anticipates an approximate price range of $[***] per share for the Company’s common stock (the “Preliminary IPO Price Range”), with a midpoint of the anticipated range of approximately $[***] per share (the “Preliminary Assumed IPO Price”). The Preliminary IPO Price Range and Preliminary Assumed IPO Price do not reflect any stock split that the Company expects to effect prior to the Commission’s declaration of effectiveness of the Registration Statement. The post-split price range will be narrowed within the Preliminary IPO Price Range prior to distribution of the preliminary prospectus in connection with the Company’s road show. For consistency with the Registration Statement, all data in this letter is reflected on a pre-split basis, unless otherwise expressly noted. The Company’s final post-split Preliminary IPO Price Range remains under discussion between the Company and the lead underwriters, and a bona fide price range will be included in an amendment to the Registration Statement prior to any distribution of the preliminary prospectus in connection with the Company’s road show. The following table summarizes the number of shares of common stock underlying stock options granted since June 30, 2020, as well as the associated per share exercise price and the estimated fair value per share of the Company’s common stock used to determine stock-based compensation expense for financial reporting purposes. (a) Represents the fair value per share of the underlying common stock for financial reporting purposes used to calculate the grant date fair value of the stock options issued on July 29, 2021 for which compensation expense will be recognized for the nine month period ended September 30, 2021. See “June 14, 2021 Valuation and Fair Value Determination” for a discussion of retrospective review of estimated fair value. HISTORICAL FAIR VALUE DETERMINATION AND METHODOLOGY The Company has historically determined the fair value of its common stock using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the “AICPA Practice Guide”). In addition, the Board of Directors also considered numerous objective and subjective factors, along with input from management and third-party valuations, to determine the fair value of the Company’s common stock as disclosed in the Registration Statement. Historically, the Company has obtained independent third-party valuations of its common stock on an annual basis as well as following events or conditions that the Company determines could cause the assumptions, qualifications or methodologies contained in prior independent third-party valuations to materially change. As described in greater detail in MD&A, (a) for valuations performed prior to June 14, 2021, the Company utilized the option-pricing model (“OPM”) backsolve method weighted against a discounted cash flow analysis for determining the fair value of its common stock, (b) for valuations performed between June 14, 2021 and prior to August 18, 2021, the Company utilized the OPM backsolve method for determining the fair value of its common stock, and (c) for the valuation performed on August 18, 2021, the Company utilized a hybrid method (the “Hybrid Method”) of the OPM and the probability-weighted expected return model (“PWERM”) for determining the fair value of the Company’s common stock. The Company used the OPM rather than the PWERM until August 2021 because specific future outcomes, such as an IPO or M&A transaction, were difficult for the Company to predict. However, the PWERM was presented in the form of a supplemental analysis to the backsolve method in the valuation performed in June 2021 reflecting a similar conclusion. In the OPM framework, the backsolve method for inferring the equity value implied by a recent financing transaction involves making assumptions for the expected time to liquidity, volatility, and risk-free rate and then solving for the value of equity by calibrating to the value of the most recent class of preferred stock. A reasonable discount for lack of marketability is then applied to conclude on a per share value of the common stock on a minority, non-marketable basis. The OPM method was selected as management concluded that the financing transactions were negotiated at arms’ length and provided the best indication of the fair value of the preferred stock at each measurement date. Under the PWERM, the per share value of the common stock is estimated based upon the probability-weighted present value of expected future equity values for the common stock, under various possible future liquidity event scenarios, in light of the rights and preferences of each class of equity, and the resulting per share value of the common stock is discounted for a lack of marketability. The Hybrid Method estimates the probability-weighted value across multiple scenarios but uses the OPM to estimate the allocation of value within one or more of the scenarios. The Company determined to incorporate the PWERM into its valuation methodology as values associated with various potential outcomes were considered estimable, in light of the Company’s stage of development, operating results, its prospects for an IPO in the near term, general conditions in the capital markets, including with respect to IPOs, and the relative likelihood of achieving a liquidity event such as an IPO in light of prevailing market conditions. At each grant date, the Board of Directors evaluated any recent events and their potential impact on the estimated per share fair value of the common stock. For grants of stock awards made on dates for which there was no concurrent independent third-party valuation, the Company’s Board of Directors determined the fair value of the common stock on the date of grant taking into consideration the immediately preceding valuation report as well as other pertinent information available at the time of the grant. DISCUSSION OF FAIR VALUE DETERMINATIONS OVER THE PAST 12 MONTHS The table below sets forth the fair market value determinations of the Company’s common stock as provided by independent third-party valuation reports for periods since June 30, 2020. The Company does not expect to make any additional grants prior to the completion of its IPO other than grants made concurrent with the IPO at an exercise price equal to the final IPO price. The Company was originally incorporated as a California company in 2007, and, in April 2021 was reincorporated into Delaware. As of June 30, 2021, the Company had raised $[***] from private placements of redeemable convertible preferred stock, including its most recent Series F and Series G redeemable convertible preferred stock financings. In July 2020, the Company sold $[***] of its Series F redeemable convertible preferred stock at an issue price of $[***] per share. The Series F redeemable convertible preferred stock financing was led by an independent third-party investor. In June 2021, the Company sold $[***] of its Series G redeemable convertible preferred stock at an issue price of $[***] per share. The Series G redeemable convertible preferred stock financing was also led by an independent third-party investor. July 30, 2020 Valuation and Fair Value Determination Concurrent with the completion of the Company’s Series F redeemable convertible preferred stock financing, the Company obtained an independent third-party valuation of the Company’s common stock as of July 30, 2020 (giving effect to the issuance of the Series F redeemable convertible preferred stock in that same month) (the “July 2020 Valuation”). The July 2020 Valuation estimated the equity value of the Company using a two-step process involving a weighted average of the fundamental analysis and the transaction analysis. The implied equity value derived from each analysis was then allocated to the Company’s common stock using the OPM. Under the fundamental analysis, the valuation relied on the market approach and income approach, together with a discounted cash flow analysis to determine an aggregate equity value of the Company. This resulted in an implied equity value, on a marketable minority interest basis, of $[***]. After allocating the implied equity value to the Company’s common stock using the OPM and applying a DLOM of 33%, the fair value per share of the common stock under the fundamental analysis was estimated at $[***] per share. The transaction analysis gave consideration to the Company’s Series F redeemable convertible preferred stock financing, and used the Backsolve Method to derive an implied total equity value from the per share sale price in that financing. This resulted in an implied equity value, on a marketable basis, of $[***]. After allocating the implied equity value to the Company’s common stock using the OPM and applying a DLOM of 33%, the fair value per share of the common stock under the transaction analysis was estimated at $[***] per share. Given that the closing of the Series F redeemable convertible preferred stock financing occurred on the valuation date, the valuation weighted the transaction analysis at 90% and the fundamental analysis at 10%. This resulted in an estimated fair value of $[***] per share. Considering the July 2020 Valuation and the objective and subjective factors described on pages 99-100 of the Registration Statement, the Company’s Board of Directors determined that the fair value of the Company’s common stock was $[***] per share as of July 30, 2020. For each grant date between July 30, 2020 and December 31, 2020, the Board of Directors considered the July 2020 Valuation together with any subsequent changes in the objective and subjective factors described on pages 99-100 of the Registration Statement, to determine the fair value of the common stock at the time of grant. At each grant date, the Board of Directors concluded that the fair value of the common stock was $[***] per share and granted options with that exercise price. December 31, 2020 Valuation and Fair Value Determination Consistent with its prior practice, the Company obtained an independent third-party valuation of the Company’s common stock as of December 31, 2020, and, based on its consideration of this valuation and the objective and subjective factors described on pages 99-100 of the Registration Statement, the Board of Directors determined that the fair value of the Company’s common stock was $[***] per share as of December 31, 2020 (the “December 2020 Valuation”). The December 2020 Valuation also estimated the equity value of the Company using a two-step process involving a weighted average of the fundamental analysis and the transaction analysis. The implied equity value derived from each analysis was then allocated to the Company’s common stock using the OPM. Under the fundamental analysis, the valuation relied on the market approach and income approach, together with a discounted cash flow analysis to determine an aggregate equity value of the Company. This resulted in an implied equity value, on a marketable minority interest basis, of $[***]. After allocating the implied equity value to the Company’s common stock using the OPM and applying a DLOM of 30%, the fair value per share of the common stock was estimated at $[***] per share. The transaction analysis gave consideration to the Company’s Series F redeemable convertible preferred stock financing, and used the Backsolve Method to derive an implied total equity value from the per share sale price in that financing. This resulted in an implied equity value, on a marketable basis, of $[***]. After allocating the implied equity value to the Company’s common stock using the OPM and applying a DLOM of 33%, the fair value per share of the common stock was estimated at $[***] per share. The increase in fair value of the common stock from the July 2020 Valuation was primarily attributable to a lesser weighting on backsolve method, which decreased from 90% in the July 2020 Valuation to 50% in the December 2020 Valuation. Given the timing of the Series F redeemable convertible preferred stock financing relative to the valuation date, the valuation weighted the fundamental analysis and the transaction analysis each at 50%. This resulted in an estimated fair value of $[***] per share. Considering the December 2020 Valuation and the objective and subjective factors described on pages 99-100 of the Registration Statement, the Company’s Board of Directors determined that the fair value of the Company’s common stock was $[***] per share as of December 31, 2020. In particular the Company noted that seven Medicare Administrative Contractors had provided positive local coverage determinations for Aquablation therapy. For the option grant dates in February and March 2021, the Board of Directors considered the December 2020 Valuation together with any subsequent changes in the objective and subjective factors described on pages 99-100 of the Registration Statement, to determine the fair value of the common stock at the time of grant. At each grant date, the Board of Directors determined that no significant subsequent changes to the business had occurred and concluded that the fair value of the common stock was $[***] per share and granted options with that exercise price. June 14, 2021 Valuation and Fair Value Determination Concurrent with the completion of the Company’s Series G redeemable convertible preferred stock financing, the Company obtained an independent third-party valuation of the Company’s common stock as of June 14, 2021 (the “June 2021 Valuation”), and, based on its consideration of this valuation and the objective and subjective factors described on pages 99-100 of the Registration Statement, the Board of Directors determined that the fair value of the Company’s common stock was $[***] per share as of June 14, 2021. The June 2021 Valuation estimated the equity value of the Company using the transaction analysis. The transaction analysis gave consideration to the Company’s Series F redeemable convertible preferred stock financing, and used the Backsolve Method to derive an implied total equity value from the per share sale price in that financing. The implied equity value derived from the transaction analysis was then allocated to the Company’s common stock using the OPM. The Company relied on the OPM Backsolve Method rather than the PWERM because specific future outcomes, such as an IPO or M&A transaction, were difficult for the Company to predict. The PWERM was presented in the form of a supplemental analysis to the backsolve method reflecting a similar outcome. The Company determined that the Series G redeemable convertible preferred stock financing was a reasonable indication of value as of the June 14, 2021 valuation date and that the terms of the financing were fairly negotiated at arm’s length and reasonably reflected the expected economics of the Company. The backsolve analysis of the Series G redeemable convertible preferred stock financing implied a $[***] per share value for the common stock. Given the preference of the Series G redeemable convertible preferred stock over the common stock, the valuation applied a 24% DLOM to determine the fair value of the common stock on a non-marketable minority basis. This resulted in an implied fair value of $[***] per share. The increase in fair value of the common stock from the December 2020 Valuation was primarily attributable to an increase in the IPO probability from zero in the December 2020 Valuation to 20% to 40% in the June 2021 valuation. Considering the June 2021 Valuation and the objective and subjective factors described on pages 99-100 of the Registration Statement, the Company’s Board of Directors determined that the fair value of the Company’s common stock was $[***] per share as of June 14, 2021. In particular the Company noted the recently closed Series G financing, that the Company had held its organizational meeting, and that it had progressed with preparing its initial submission of the Registration Statement. For the grants made in July 2021, the Board of Directors considered the June 2021 Valuation together with any subsequent changes in the objective and subjective factors described on pages 99-100 of the Registration Statement, to determine the fair value of the common stock at the time of grant. At that time the Board of Directors determined that the fair value of the common stock on the date of the July 2021 option grants was $[***] per share and granted options with that exercise price. Subsequently, following the adoption of a fair value in August 2021 of $[***] per share, the Company determined to retrospectively evaluate the fair value for financial reporting purposes of the option grants in July 2021. In performing this evaluation, the Company considered the feedback from additional investor meetings occurring after the June Valuation, its continued progress towards an IPO, but measured against uncertainty caused by the Delta variant of the SARS-CoV-2 virus in the market as well in the ability of hospitals to continue performing Aquablation therapy procedures. Based on this analysis, the Company adjusted the fair value of the Common Stock for financial reporting purposes for the July 2021 grant date to $[***] per share utilizing a linear interpolation from the June 2021 Valuation. The Company believes that a linear interpolation is appropriate as no single event caused the valuation of the Company’s common stock to fluctuate. Instead, a combination of Company-specific factors, including its progress toward an IPO, more certainty around the Company’s business and financial position as well as external market factors, led to the changes in the fair value of the underlying common stock. August 13, 2021 Valuation and Fair Value Determination The Company obtained an independent third-party valuation of the Company’s common stock as of August 13, 2021 (the “August 2021 Valuation”), and, based on its consideration of this valuation and the objective and subjective factors described on pages 99-100 of the Registration Statement, the Board of Directors determined that the fair value of the Company’s common stock was $[***] per share as of August 13, 2021. The August 2021 Valuation utilized the Hybrid Method of the OPM and the PWERM for determining the fair value of the Company’s common stock. The transition to the Hybrid Method was based on the Company’s progress towards a potential IPO. The August 2021 Valuation weighted 30% to the OPM and 70% to the PWERM. For purposes of the OPM, the independent third-party valuation estimated the equity value of the Company using the same transaction approach and Backsolve Method of the OPM utilized in the June 2021 Valuation. The backsolve analysis of the Series G redeemable convertible preferred stock financing implied a $[***] per share value for the common stock. Given the preference of the Series G redeemable convertible preferred stock over the common stock, the valuation applied a DLOM to determine the fair value of the common stock on a non-marketable minority basis. This resulted in an implied fair value of $[***] per share. For PWERM purposes, the Company utilized five potential scenarios, which included (1) an acquisition of the Company; (2) a low IPO, (3) a base IPO, (4) a high IPO and (5) a pre-emptive acquisition transaction. The Board of Directors, in consultation with management, weighted the probability of each scenario as follows: For purposes of the PWERM, to derive its equity value in each of the potential liquidity scenarios, the independent third-party valuation utilized input from management together with market-based data. The Company believes that the potential future scenarios used in the August 2021 Valuation and the probability weighting of each future scenario was appropriate at the time, in light of the Company’s stage of commercialization, development of the business, and the feasibility of completing an IPO. The PWERM determined a present value and then applied a DLOM of 15% to arrive at a fair value per share of $[***]. Utilizing the estimated fair values from both the OPM and the PWERM, and applying the probability weighting, the independent third-party valuation derived an aggregate probability weighted fair value per common share, on a non-marketable minority interest basis, of $[***] per share. Considering the August 2021 Valuation and the objective and subjective factors described on pages 99-100 of the Registration Statement, the Company’s Board of Directors determined that the fair value of the Company’s common stock was $[***] per share as of August 13, 2021. In performing this valuation, the Company considered the feedback from additional investor meetings occurring after the June 2021 Valuation, its continued progress towards an IPO, but measured those advances against uncertainty caused by the Delta variant of the SARS-CoV-2 virus in the market as well in the ability of hospitals to continue performing Aquablation therapy procedures. At the August grant date, the Board of Directors concluded that the fair value of the common stock was $[***] per share and granted options with that exercise price. As noted above, the Preliminary IPO Price Range is $[***] per share, with a Preliminary Assumed IPO Price of approximately $[***] per share. The Preliminary IPO Price Range was derived using a combination of valuation methodologies, including, among other methodologies: •a comparison of the Company’s post-money valuation at the conclusion of its last round of financing to step-up valuations for comparable companies pursuing an IPO following their respective last rounds of financings; •a comparison of comparable company valuations at the time of their respective IPOs; •a comparison of public companies at a similar stage of development; •a comparison of the valuation increases for comparable companies at the time of their respective IPOs; •feedback from prospective investors as a result of testing the waters meetings; and •recent market conditions used in the determination of the Preliminary Price Range after discussions with the Representatives, based on the current market environment and the supply and demand for such investment opportunities in the marketplace. COMPARISON OF PRELIMINARY IPO PRICE RANGE AND ESTIMATED EQUITY FAIR VALUE PER SHARE For the equity awards granted in August 2021, there are a number of factors that account for the increase in the Preliminary IPO Price Range over the applicable grant date fair value used for determining stock-based compensation expense. These include: •the Preliminary IPO Price Range does not take into account the current lack of liquidity for the Company’s common stock and assumes a successful IPO with no weighting attributed to any other outcome for the Company’s business, such as remaining a privately held company or being sold in an acquisition transaction. •As is typical for IPOs, the Preliminary IPO Price Range was not derived using a formal determination of fair value, but was determined as a result of discussions among representatives of the Company’s management, Board of Directors, and the underwriters. Conversely, the Company’s valuation methodologies, which are both commonly accepted and applied in the valuation community and are consistent with the methods and guidance in the AICPA Practice Guide, reflect the potential for alternative liquidity events occurring at different future dates, which inherently decreases the estimated fair value per share due to the combination of (i) the discounting to present value for each of the future business values upon a liquidity event; and (ii) the application of a discount for lack of marketability. •The Preliminary IPO Price Range was neither reduced by the expected future business values (discounted to present value) from other potential future liquidity events nor discounted for a lack of marketability. Notably, the equity values used in the near-term IPO scenarios for the August 2021 Valuation are consistent with the pre-offering equity value at the mid-point of the Preliminary IPO Price Range. •Upon completion of the IPO, all of the Company’s outstanding redeemable convertible preferred stock would automatically convert to common stock and the associated preferred stock rights, including liquidation rights, would be eliminated. •The successful completion of the IPO would strengthen the Company’s balance sheet, provide access to public equity, increase visibility with acquirors, increase the Company’s strategic flexibility and provide enhanced operational flexibility to potentially obtain regulatory approval for and commercialize the Company’s product candidates. In conclusion, the Company believes that the deemed per share fair values of its common stock used as the basis for determining the stock-based compensation expense for financial reporting purposes are reasonable and appropriate, and the Company respectfully submits that the differences from the Preliminary IPO Price Range are reasonable in light of all of the considerations outlined above. In addition, the Company will continue to update its disclosure for all equity-related transactions through the effective date of the Registration Statement. Based on the foregoing, the Company respectfully seeks confirmation that the Staff has no further comments with respect to the matters discussed in this letter. We thank you in advance for your consideration of the foregoing. Please do not hesitate to contact me by telephone at (714) 755-8181 with any questions or comments regarding this correspondence.

One letter for all the questions, without numbered answers. Read the reply
Draft Registration Statement on Form S-1 submitted June 25, 2021 · Market and Industry Data, page ii
SEC asked (2)
Please clarify the meaning of scientific or technical terms the first time they are used here and in the Business section or in close proximity thereto in order to ensure that lay readers will understand the disclosure. For example, please briefly explain what you mean by cystoscopic, endoscopic, CPU, resective surgery, hemostatis and peri-operative transfusion.
PRCT answered

See the reply above.

Draft Registration Statement on Form S-1 submitted June 25, 2021 · Market and Industry Data, page ii
SEC asked (3)
We note your disclosure on pages 38 and 125 that your currently marketed AquaBeam Robotic System is a Class II medical device, which was initially granted marketing authorization pursuant to a de novo classification. Please revise to include disclosure of the Class II classification in the Summary as well.
PRCT answered

See the reply above.

Draft Registration Statement on Form S-1 submitted June 25, 2021 · Market and Industry Data, page ii
SEC asked (4)
We note your disclosure on pages 1, 4 and throughout the Business section that your Aquablation therapy delivers outcomes that are “effective, safe and durable” across all prostate sizes and shapes. Please note that determinations of safety and efficacy are solely within the authority of the FDA and comparable foreign regulators; therefore, please revise the prospectus to remove all references and/or implications of
Rest of the question

safety and efficacy for the use of your devices in treating indications for which you have not received an approved PMA from the FDA.

PRCT answered

See the reply above.

Draft Registration Statement on Form S-1 submitted June 25, 2021 · Market and Industry Data, page ii
SEC asked (5)
Please revise to explain when you commenced work designing the AquaBeam Robotic System, when you conducted the studies referenced in the prospectus and when your product received 510(k) clearance. Please also include a detailed description of the patient population for which your AquaBeam Robotic System for which you have received FDA 510(k) clearance.
PRCT answered

See the reply above.

Our Solution, page 3
SEC asked (6)
Please balance your disclosure with equally prominent disclosure of the disadvantages of your AquaBeam Robotic System, such as observed hemostatis, peri-operative transfusions and any other adverse side effects observed in your clinical trials, as applicable. Our Success Factors, page 4
PRCT answered

See the reply above.

Our Solution, page 3
SEC asked (7)
We refer to your disclosure on page 4 and elsewhere in the prospectus to nine clinical studies and over 100 peer-reviewed publications demonstrating the efficacy, safety and durability of your Aquablation therapy.
Rest of the question

Please revise your disclosure in this section and in greater detail elsewhere to disclose, if true, whether you funded or sponsored the clinical studies and if your employees were involved in both the studies and publications.

PRCT answered

See the reply above.

Summary Risk Factors, page 6
SEC asked (8)
Please disclose as a principal risk factor the risk of substantial dilution as discussed on page 65. Also when discussing the risk of dilution in the risk factors section, please discuss the affect that the redeemable convertible preferred stock may have upon dilution.
PRCT answered

See the reply above.

We depend on third-party suppliers..., page 22
SEC asked (9)
We note your risk factor disclosure on page 22 that for certain critical components and raw materials for your products, you rely on single source suppliers and for which there are relatively few alternative sources of supply. Please expand your disclosure in the Business section to discuss your sources, the availability of raw materials and the names of any principal suppliers.
Rest of the question

See Item 101(h)(4)(v) of Regulation S-K. Delaware law and provisions in our amended and restated certificate of incorporation..., page 66

PRCT answered

See the reply above.

We depend on third-party suppliers..., page 22
SEC asked (10)
We note your disclosure that the forum selection provision in your amended certificate of incorporate may have the effect of discouraging lawsuits against you and your directors and officers. Please revise this risk factor and your disclosure in the Business section to disclose that there is also a risk that your forum selection provision may result in increased costs for investors to bring a claim.
PRCT answered

See the reply above.

Components of Our Results of Operations, page 83
SEC asked (11)
We note your disclosure on page 83 that sales of your products outside the United States represented that approximately 66% and 47% of revenue for the years ended December 31, 2019 and 2020. You also disclose on page 102 that you are growing your existing presence in the large European markets, including Germany, France, Italy, Spain and the United Kingdom.
Rest of the question

Please expand your disclosure here to identify the key foreign markets that represented the sales of your products outside of the United States.

PRCT answered

See the reply above.

Critical Accounting Policies and Estimates · Common Stock Valuations, page 94
SEC asked (12)
Once you have an estimated offering price or range, please explain to us how you determined the fair value of the common stock underlying your equity issuances and the reasons for any differences between the recent valuations of your common stock leading up to the IPO and the estimated offering price.
Rest of the question

This information will help facilitate our review of your accounting for equity issuances, including stock compensation. Please discuss with the staff how to submit your response.

PRCT answered

See the reply above.

Business, page 97
SEC asked (13)
We refer to your disclosure on page 98 under the first bullet point under the heading “Significant and durable symptom relief” and the surgical retreatment rates observed in your clinical studies. Please balance your disclosure to describe the surgical retreatment rates observed for patients who underwent TURP and other treatments, as applicable. We refer to your disclosure on page 116.
PRCT answered

See the reply above.

Market Overview, page 102
SEC asked (14)
We note your disclosure on page 105 relating to dissatisfaction among patients with the effectiveness of their BPH medications. We also refer to your disclosure in the first bullet point on page 106 of your belief that the high rates of irreversible complications are largely due to use of heat-based technology to resect prostate tissue. Please revise to clarify the studies and the data that support your conclusions.
PRCT answered

See the reply above.

Our Clinical Results and Studies, page 111
SEC asked (15)
Please revise to clarify whether each of your core clinical trials were powered for statistical significance and expand your discussion of the statistical significance and pvalues with respect to improvements in IPSS and QoL scores, surgical retreatment rates and operative times, as applicable.
PRCT answered

See the reply above.

Our Clinical Results and Studies, page 111
SEC asked (16)
Please expand on the significance of peri-operative transfusion rates and hemostatis observed in your core clinical studies, including how the transfusion rates and hemostatis observed compare to TURP and other alternative surgical treatments.
PRCT answered

See the reply above.

Our Clinical Results and Studies, page 111
SEC asked (17)
We note your disclosure that you plan to follow patients in the WATER and WATER II clinical studies for a total of five years, with three-year data already having been collected and analyzed. Please clarify your follow-up plans for patients in your OPEN WATER clinical study beyond the 12-month follow-up.
PRCT answered

See the reply above.

Intellectual Property, page 123
SEC asked (18)
We note your disclosure on page 123 relating to your patent portfolio in the U.S. and in foreign jurisdictions. Please expand your disclosure to identify for each material patent and patent application, as applicable, the scope and technology of each such patent or patent application, the type of patent protection and expiration dates. Consider adding tabular disclosure in addition to the narrative for ease of use.
PRCT answered

See the reply above.

Intellectual Property, page 123
SEC asked (19)
You disclose on page 62 that you are dependent on intellectual property licensed from third parties, including AquaBeam LLC. To the extent material, please expand your disclosure in this section to disclose any additional third parties from whom you license intellectual property, the scope of and technology related to such patent rights and the material terms of such license agreements.
Rest of the question

Please also revise your disclosure here and in the risk factor disclosure section to identify AquaBeam LLC as an entity affiliated with your company.

PRCT answered

See the reply above.

License Agreement with AquaBeam, page 124
SEC asked (20)
Please revise to disclose when the last-to-expire licensed patent and PROCEPT Patent is set to expire under the AquaBeam license agreement. Please also disclose the upfront fee and the aggregate amount of milestone payments to be paid or received, if any, as well as the aggregate amounts paid or received under the license agreement.
PRCT answered

See the reply above.

Principal Stockholders, page 152
SEC asked (21)
In your revised prospectus, please include in the footnotes to your table to identify the natural persons who are the beneficial owners of the shares held by Viking Global Opportunities Illiquid Investments Sub-Master LP and for the Entitles Associated with Fidelity, as well as the address of each such natural person, as applicable.
PRCT answered

See the reply above.

Note 2. Summary of Significant Accounting Policies · Revenue Recognition, page F-12
SEC asked (22)
We note that you record revenue for both the sale and rental of equipment and that on page F-18 you have $1.2 million of capitalized rental equipment. Please revise the filing to clearly describe the accounting treatment for your rental revenue, including general or material terms of the lease agreements including any minimum purchase commitments. Tell us how your accounting treatment complies with ASC 842.
Rest of the question

Tell us and disclose, if material, the amount of rental revenue that is outside the scope of ASC 606. Refer to ASC 606-10-50-4(a).

PRCT answered

See the reply above.

General
SEC asked (23)
Please provide us with supplemental copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, have presented or expect to present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not you retained, or intend to retain, copies of those communications.
PRCT answered

See the reply above.

Our Clinical Results and Studies, page 114
SEC asked (1)
We note your response to our prior comment 16. To the extent known, please expand your disclosure to address how the transfusion rates and hemostatis observed in your clinical studies compare to TURP and other alternative surgical treatments. Intellectual Property, page 126
PRCT answered
In response to the Staff’s comment, the Company has revised its disclosure on page 123 of the Registration Statement.
Read in the reply
Our Clinical Results and Studies, page 114
SEC asked (2)
We note your response to our prior comment 18. Please revise your disclosure to specify the type of patent protection afforded to the material patents covering your AquaBeam Robotic System (e.g., composition of matter, use or process). Please also identify the jurisdictions of the 25 foreign patents covering your AquaBeam Robotic System.
PRCT answered
In response to the Staff’s comment, the Company has revised its disclosure on pages 129 to 130 of the Registration Statement.

We hope that the foregoing has been responsive to the Staff’s comments and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact me at 714-755-8008 with any questions or further comments you may have regarding this filing or if you wish to discuss the above.
Read in the reply
Intellectual Property, page 129
SEC asked
We note your response to our prior comment 2. You disclose on page 129 that 9 of the 26 issued U.S. patents and 31 of the 70 issued or granted foreign patents cover aspects of your AquaBeam Robotic System and current and future product concepts. Please expand your disclosure of the remaining issued U.S.
Rest of the question

and foreign patents as well to include the products or technologies to which such patents relate and the type of patent protection provided.

PRCT answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 128 to 129 of Amendment No. 1.

We hope that the foregoing has been responsive to the Staff’s comments and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact me at 714-755-8181 with any questions or further comments you may have regarding this filing or if you wish to discuss the above.
Read in the reply

Also in this review: company letter, Sep 10, 2021, company letter, Sep 10, 2021

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 8 letters filed since 2021-07-23. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PRCT/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.